The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the newest β-lactam/β-lactamase inhibitors (BL/BLIs) introduced to the North American antibiotic market. All have broad Gram-negative activity, including against certain carbapenemases. Despite this, susceptibility testi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical microbiology 2022-07, Vol.60 (7), p.e0080721
Main Authors: Dingle, Tanis C, Pitout, Johann
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Bacterial Proteins - genetics
beta-Lactamase Inhibitors - pharmacology
beta-Lactamase Inhibitors - therapeutic use
beta-Lactamases - genetics
Ceftazidime - pharmacology
Clinical Microbiology
Drug Combinations
Humans
Lactams
Microbial Sensitivity Tests
Minireview
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the newest β-lactam/β-lactamase inhibitors (BL/BLIs) introduced to the North American antibiotic market. All have broad Gram-negative activity, including against certain carbapenemases. Despite this, susceptibility testing is warranted due to variable activity against certain β-lactamases (e.g., oxacillinases) and the presence of acquired resistance mechanisms in some isolates. Here, we discuss what we know about these new antimicrobial agents and how to navigate implementation of susceptibility testing and reporting of these agents in clinical laboratories.
ISSN:0095-1137
1098-660X
1098-660X
DOI:10.1128/jcm.00807-21